Kymera Therapeutics Management
Management criteria checks 2/4
Kymera Therapeutics' CEO is Nello Mainolfi, appointed in Jun 2019, has a tenure of 5.42 years. total yearly compensation is $9.67M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 1% of the company’s shares, worth $28.63M. The average tenure of the management team and the board of directors is 3.5 years and 3.9 years respectively.
Key information
Nello Mainolfi
Chief executive officer
US$9.7m
Total compensation
| CEO salary percentage | 6.6% |
| CEO tenure | 5.4yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.5yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Oct 06Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$167m |
| Jun 30 2024 | n/a | n/a | -US$158m |
| Mar 31 2024 | n/a | n/a | -US$155m |
| Dec 31 2023 | US$10m | US$640k | -US$147m |
| Sep 30 2023 | n/a | n/a | -US$167m |
| Jun 30 2023 | n/a | n/a | -US$158m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$7m | US$600k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$139m |
| Mar 31 2022 | n/a | n/a | -US$124m |
| Dec 31 2021 | US$12m | US$571k | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$48m |
| Dec 31 2020 | US$4m | US$454k | -US$55m |
| Sep 30 2020 | n/a | n/a | -US$53m |
| Jun 30 2020 | n/a | n/a | -US$57m |
| Mar 31 2020 | n/a | n/a | -US$52m |
| Dec 31 2019 | US$2m | US$362k | -US$41m |
Compensation vs Market: Nello's total compensation ($USD9.67M) is above average for companies of similar size in the US market ($USD6.57M).
Compensation vs Earnings: Nello's compensation has increased whilst the company is unprofitable.
CEO
Nello Mainolfi (45 yo)
5.4yrs
Tenure
US$9,670,542
Compensation
Dr. Nello Mainolfi, M.D., Ph D., is Co-Founder, President, Chief Executive Officer and Director at Kymera Therapeutics, Inc. since November 2019. Previously, at Kymera Therapeutics, Dr. Mainolfi served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.2yrs | US$266.46k | 0% $ 0 | |
| Co-Founder | 5.4yrs | US$9.67m | 1% $ 28.6m | |
| Chief Financial Officer | 5.3yrs | US$4.16m | 0.18% $ 5.2m | |
| Chief Operating Officer | 1.5yrs | US$5.19m | 0.0089% $ 253.6k | |
| Chief Legal Officer & Corporate Secretary | 1.8yrs | US$4.97m | 0.0094% $ 267.9k | |
| Chief Medical Officer | 6.2yrs | US$3.47m | 0.084% $ 2.4m | |
| Head of People & Culture | 2.5yrs | no data | no data | |
| Head of Research | 3.5yrs | no data | no data |
3.5yrs
Average Tenure
59yo
Average Age
Experienced Management: KYMR's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.2yrs | US$266.46k | 0% $ 0 | |
| Co-Founder | 5yrs | US$9.67m | 1% $ 28.6m | |
| Independent Director | 2.8yrs | US$236.46k | 0% $ 0 | |
| Lead Independent Director | less than a year | no data | no data | |
| Independent Director | 3.7yrs | US$246.46k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$246.46k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$241.46k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$243.96k | 0% $ 0 | |
| Independent Director | 2yrs | US$231.46k | 0% $ 0 | |
| Independent Director | 4.7yrs | US$236.46k | 0% $ 0 |
3.9yrs
Average Tenure
51.5yo
Average Age
Experienced Board: KYMR's board of directors are considered experienced (3.9 years average tenure).